CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

19-386/S-021

Chemistry Review(s)

CHEMIST'S REVIEW	1. ORGANIZATION HFD-110	2. NDA Number 19–386
3. Name and Address of Applicant (City & State) Baxter Pharmaceutical Products Inc. 95 Spring Street New Providence, NJ 07974		4. Supplement(s) Number(s) Date(s) SCF-021 10/24/02
5. Drug Name Brevibloc	6. Nonproprietary Name Esmolol HCl	7. Amendments & Other (reports, etc) Dates Amendment of 01/13/03 EA Exclusion Certification. References: Approval letter of supplement #S018 of 2/16/01 & firm's proposal of 9/5/01
8. Supplement Provides For: New Isotonic Formulation of Brevibloc Injection, 10 mg/mL in 10 mL vials with reduced overage of Active Ingredient from the approved –% to overage –% (as per phase 4 commitment). Also this submission provides for [redacted] vial in place of the currently used [redacted] vial.		
9. Pharmacological Category Anti–adrenergic (β receptor)	10. How Dispensed ☒Rx ☐OTC	11. Related IND(s)/ NDA(s)/DMF(s) Type II, DMF [redacted] & [redacted]
12. Dosage Form(s) Intravenous injection	13. Potency(ies) 10 mg/mL in 10 mL ready to use vials	
14. Chemical Name and Structure (±) methyl p–[2–hydroxy–(isopropylamino)propoxyl] hydrocinnamate hydrochloride Molecular weight: 331.8 $C_{16}H_{25}NO_4$.HCl  esmolol		15. Records/Reports Current ☒Yes ☐No Reviewed ☒Yes ☐No

16. **Comments:**
Firm has provided the 3 months stability data in the ready to use new isotonic formulation containing NaCl, in the 10 mL vials. Firm has also provided the manufacturing formula and executed batch records of the three qualification batches in this supplement with reduced overage, of Brevibloc Injection 10 mg/mL in ready to use 10 mL vials. Firm has provided the revised labeling which reflects introduction of the isotonic agent, sodium chloride, USP, but immediate container label should also contain composition statement. Firm has now on our request, in an amendment of 01/11/03, sent the Environment Assessment Categorical Exclusion Certification.

Cont'd

17. **Conclusions and Recommendations**
This P.A. supplement may be approved from the standpoint of chemistry. Refer also microbiological review of Dr. Pawar dated 01/22 /03 and draft labeling review of Dr. Shari Targum dated 01/09/03, filed with this supplement. The immediate container label should be revised. It should contain composition statement as it is in the current label.

18. **REVIEWER**

Name	Signature	Date Completed
JV Advani		Jan. 30, 2003

Distribution: ☒ Original Jacket ☒ Reviewer ☒ Division File ☒ CSO

Redacted 4

pages of trade

secret and/or

confidential

commercial

information

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

J. V. Advani
2/14/03 06:53:31 AM
CHEMIST

Kasturi Srinivasachar
2/14/03 09:05:46 AM
CHEMIST